+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Proton Pump Inhibitors Increase the Overall Risk of Developing Bacterial Infections in Patients with Cirrhosis



Proton Pump Inhibitors Increase the Overall Risk of Developing Bacterial Infections in Patients with Cirrhosis



Arquivos de Gastroenterologia 55(1): 28-32



Acid suppression has been associated with adverse events; such as, enteric infections. Proton pump inhibitors (PPI) are frequently prescribed in patients with cirrhosis, but is unclear if PPI are associated with the development of bacterial infections in these patients. To assess the impact of PPI intake on the development of bacterial, viral and fungal infections in patients with cirrhosis. An observational, retrospective, historic cohort study. The exposed cohort included patients with cirrhosis with chronic use of PPI. The non-exposed cohort had not been using PPI. The follow-up period was 3 years, searching in the medical records for any events of bacterial infection confirmed by bacteriological culture. One hundred and thirteen patients met the selection criteria, 44 (39%) had chronic use of PPI; of them, 28 (63.6%) patients had not a clear clinical indication to justify the prescription of PPI. Twenty four (21.2%) patients developed bacterial infections during the follow-up period. In the univariate analysis, decompensated cirrhosis (Child B/C), presence of ascites, history of variceal bleeding, and chronic consumption of PPI were risk factors related to the development of infections. But, in the adjusted multivariate analysis only the chronic use of PPI was associated with development of infections (RR=3.6; 95% CI=1.1-12.3; P=0.04). There is an over-prescription of PPI without a justified clinical indication. The long-term consumption of PPI in patients with cirrhosis is associated with the development of bacterial infections; therefore these drugs must be carefully prescribed in this specific population.

(PDF emailed within 0-6 h: $19.90)

Accession: 065445507

Download citation: RISBibTeXText

PMID: 29561973

DOI: 10.1590/S0004-2803.201800000-09


Related references

Proton pump inhibitors do not increase the risk for recurrent spontaneous bacterial peritonitis in patients with cirrhosis. Journal of Gastroenterology and Hepatology 32(5): 1064-1070, 2017

Subsequent Bacterial Infections in Patients With Cirrhosis and the Role of Proton-Pump Inhibitors. Clinical Gastroenterology and Hepatology 13(11): 2026-2027, 2016

Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study. Gastroenterology 152(1): 134-141, 2016

Effect of proton pump inhibitors on the risk and prognosis of infections in patients with cirrhosis and ascites. Liver International 2018, 2018

Risk of small intestinal bacterial overgrowth in patients receiving proton pump inhibitors versus proton pump inhibitors plus prokinetics. Jgh Open 2(2): 47-53, 2018

Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites. Hepatology 64(4): 1265-1272, 2017

Bacterial infections in cirrhosis: role of proton pump inhibitors and intestinal permeability. European Journal of Clinical Investigation 42(7): 760-767, 2012

The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. Liver International 35(2): 362-369, 2015

Effect of Proton Pump Inhibitors on Mortality in Patients with Cirrhosis and Spontaneous Bacterial Peritonitis. Annals of Hepatology 17(6): 933-939, 2019

Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth. Journal of Gastroenterology 53(1): 27-36, 2017

Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. Clinical Gastroenterology and Hepatology 13(4): 753-9.E1-2, 2015

Bacterial load and cytokine profile in patients with cirrhosis following therapy with proton pump inhibitors: a prospective cohort study. Annals of Gastroenterology 30(4): 450-456, 2017

Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites. Plos One 9(11): E110503, 2015

Proton Pump Inhibitors Did Not Increase Risk of Pneumonia in Patients With Chronic Obstructive Pulmonary Disease. Journal of Clinical Medicine Research 7(11): 880-883, 2015

Increased Risk of Spontaneous Bacterial Peritonitis in Cirrhotic Patients Using Proton Pump Inhibitors. Ge Portuguese Journal of Gastroenterology 26(2): 83-89, 2019